These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38314657)

  • 1. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
    Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
    Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
    Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
    Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?
    Cooper M; Smith S; Williams T; Aguiar-Ibáñez R
    J Med Econ; 2022; 25(1):260-273. PubMed ID: 35060433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the loss of lifetime function using flexible parametric relative survival models.
    Jakobsen LH; Andersson TM; Biccler JL; El-Galaly TC; Bøgsted M
    BMC Med Res Methodol; 2019 Jan; 19(1):23. PubMed ID: 30691400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
    Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
    BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
    Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
    MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
    Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
    BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapolation of Survival Curves from Cancer Trials Using External Information.
    Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ
    Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer.
    Andersson TM; Rutherford MJ; Lambert PC
    BMC Med Res Methodol; 2019 Jul; 19(1):145. PubMed ID: 31288739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
    Monnickendam G
    Value Health; 2024 Jun; 27(6):746-754. PubMed ID: 38428815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
    Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
    Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
    Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
    BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
    Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
    Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
    Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
    Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the loss in expectation of life due to cancer using flexible parametric survival models.
    Andersson TM; Dickman PW; Eloranta S; Lambe M; Lambert PC
    Stat Med; 2013 Dec; 32(30):5286-300. PubMed ID: 24038155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.
    Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
    Med Decis Making; 2022 Oct; 42(7):945-955. PubMed ID: 35769004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
    Gallacher D; Kimani P; Stallard N
    Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
    Che Z; Green N; Baio G
    Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.